Columbia Laboratories Receives Outstanding Regional Employer Award from RESOLVE: The National Infertility Association
LIVINGSTON, N.J.--(BUSINESS WIRE)--RESOLVE: The National Infertility Association, in partnership with Organon USA Inc., presented Columbia Laboratories, Inc. (NASDAQ: CBRX) with the 2007 Outstanding Regional Employer Award in recognition of the Company’s commitment to its employees and their desire to have the family of their dreams through medical benefits that include coverage for fertility and reproductive issues.
Though based in New Jersey, a mandated infertility benefits State, Columbia Laboratories falls outside the State mandate requirements due to its employee size. However, recognizing the importance of family building to its employees, Columbia Laboratories has chosen to offer a generous package of infertility treatment benefits to its employees. Offering up to four egg retrieval cycles, Columbia’s benefits include all diagnostics, medications, surgery, and assisted reproductive technologies including IVF and ICSI.
“The belief that all employees deserve the chance to achieve their hopes and dreams of parenthood is integral to Columbia Laboratories. Just as our natural bioadhesive progesterone gel products afford women facing infertility a better chance to achieve and maintain pregnancy, so do we support our employees’ family-building dreams through a comprehensive package of infertility treatment benefits. I thank RESOLVE for this award, which I am proud to accept on behalf of the Columbia Laboratories team,” stated Robert S., Mills, president and chief executive officer.
Founded in 1974, RESOLVE: The National Infertility Association is the oldest and largest consumer-based, nonprofit group that provides education, advocacy and compassionate support for those struggling with infertility in the United States. Each year, RESOLVE and its nationwide network of affiliates and chapters handle more than 1.5 million contacts from people seeking information and help. Additional information is available online at www.resolve.org.
About Columbia Laboratories
Columbia Laboratories, Inc. is a is a specialty pharmaceutical company focused on developing and marketing products for the women’s healthcare and endocrinology markets using its novel bioadhesive drug delivery technology. Columbia markets CRINONE® 8% (progesterone gel) and PROCHIEVE® 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT® (testosterone buccal system) for the treatment of hypogonadism in men. The Company’s research and development programs include a vaginally-administered lidocaine product to prevent and treat dysmenorrhea. For more information, please visit www.columbialabs.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.’s expectations regarding the Company’s strategic direction, prospects and future results, and clinical research programs, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE® 8% (progesterone gel), PROCHIEVE® 8% (progesterone gel), PROCHIEVE 4% (progesterone gel), and STRIANT® (testosterone buccal system) in the U.S.; the timely and successful development of new products, including determining the clinical and regulatory path for possible development of PROCHIEVE 8% for the prevention of preterm birth; the timely and successful completion of clinical studies, including the clinical studies for our vaginally-administered lidocaine product candidate; success in obtaining acceptance and approval of new products and new indications for current products by the FDA and international regulatory agencies, the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia’s reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.
CRINONE®, PROCHIEVE® and STRIANT® are registered trademarks of Columbia Laboratories, Inc.